bluebird bio - BLUE Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings or view top-rated stocks.

9 analysts have issued 12 month price targets for bluebird bio's stock. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they expect the company's share price to reach $6.75 in the next year. This suggests a possible upside of 1.4% from the stock's current price.
View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts.

bluebird bio's stock was trading at $6.92 on January 1st, 2023. Since then, BLUE stock has decreased by 3.8% and is now trading at $6.66.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, March 3rd 2023.
View our BLUE earnings forecast.

bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings results on Friday, November, 5th. The biotechnology company reported ($3.16) earnings per share for the quarter, missing analysts' consensus estimates of ($2.65) by $0.51. The biotechnology company earned $22.70 million during the quarter, compared to analysts' expectations of $39.07 million. bluebird bio had a negative trailing twelve-month return on equity of 173.58% and a negative net margin of 8,828.28%. The business's quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the firm posted ($2.94) earnings per share.

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

bluebird bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%), Los Angeles Capital Management LLC (0.15%), Hennion & Walsh Asset Management Inc. (0.12%), Monaco Asset Management SAM (0.06%), Monaco Asset Management SAM (0.06%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Richard A Colvin, Thomas J Klima and William D Baird III.
View institutional ownership trends.

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLUE stock can currently be purchased for approximately $6.66.

bluebird bio (NASDAQ:BLUE) has a market capitalization of $552.25 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819,380,000.00 in net income (profit) each year or ($6.10) on an earnings per share basis.

The company employs 518 workers across the globe.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.